Table 2.

Observed and expected number of second malignancies in patients with renal cortical neoplasms

Site	No. of observed	No. of expected	SIR (95 % CI)	p value
Male (n = 1972)
Prostate	87	73.2	1.19 (0.95–1.47)	0.063
Colorectal	20	20.1	1.0 (0.61–1.54)	0.450
Bladder	16	16.0	1.0 (0.57–1.62)	0.434
Lung	15	33.1	0.45 (0.25–0.75)	<.001
Non-Hodgkin’s lymphoma	13	8.4	1.55 (0.82–2.65)	0.085
Thyroid	6	1.2	5.0 (1.83–10.88)	0.002
Melanoma	5	8.8	0.57 (0.18–1.33)	0.128
Pancreas	5	5.0	1.0 (0.32–2.33)	0.383
Female (n = 1094)
Breast	12	25.3	0.47 (0.24–0.83)	0.003
Colorectal	10	6.5	1.54 (0.74–2.83)	0.122
Lung	9	12.5	0.72 (0.33–1.37)	0.201
Endometrium	6	5.4	1.11 (0.41–2.42)	0.453
Thyroid	6	1.3	4.62 (1.69–10.05)	0.003
Stomach	5	1.0	5.0 (1.61–11.67)	0.004

Types of cancers with incidence n < 5 in men or women are not shown

Bold numbers include those with significantly higher observed than expected rates

SIR standard incidence ratio